Merck’s investigational ADC with R-CHP demonstrates 100% response rate for B-cell lymphoma
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
For people with relapsed or refractory diffuse large B-cell lymphoma
Aster DM Healthcare and Quality Care India Limited have signed definitive agreements to merge, subject to regulatory, corporate and shareholders’ approvals
She will be responsible in this role for Finance & Controlling, HR Services and IT Management at Romaco Holding
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The 254-bedded Aster Aadhar Hospital, Kolhapur is the city's most comprehensive multi-speciality hospital
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
The centre features a cutting-edge climatic chamber for stability testing and spectrophotometry to ensure that products meet the most stringent manufacturing and testing standards
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Subscribe To Our Newsletter & Stay Updated